High-dose vitamin D supplementation reduces disease activity in clinically isolated syndrome typical of MS, results of a ...

Patients with asthma who used depemokimab tolerated treatment well while experiencing reductions in rates of clinically ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the pivotal ADEPT Phase 2/3 trial evaluating the ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

Dupixent late-breaking positive pivotal data in bullous pemphigoid presented at AAD Five times more adults on Dupixent achieved sustained disease remission at 36 weeks compared to placebo; significant ...

The US government has a further option for the supply of another 500 million doses in the longer term. Sanofi is leading the clinical development and registration of the COVID-19 vaccine and ...

Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...

In the trials, omalizumab and multi-allergen oral immunotherapy showed alike efficacy in protecting against food allergies, ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi presented positive results ... every two weeks after an initial loading dose or placebo (n=53) added to standard-of-care oral ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...